Essex Bio-Technology’s Phase 3 Study for Wet-AMD Treatment Meets Primary Endpoint

Essex Bio-Technology ( (HK:1061) ) has shared an update.

Essex Bio-Technology Limited announced that its phase 3 clinical study for the co-developed product HLX04-O, in collaboration with Shanghai Henlius Biotech, Inc., has successfully met its primary endpoint. The study, conducted on Chinese patients with wet-AMD, demonstrated that HLX04-O is non-inferior to ranibizumab in improving visual acuity and has a comparable safety profile. This achievement marks a significant milestone in the company’s efforts to advance its ophthalmic drug offerings and strengthens its position in the bio-pharmaceutical market.

More about Essex Bio-Technology

Essex Bio-Technology Limited is a company incorporated in the Cayman Islands, focusing on the bio-pharmaceutical industry. The company specializes in developing recombinant anti-vascular endothelial growth factor humanized monoclonal antibodies for treating exudative (wet) age-related macular degeneration.

YTD Price Performance: 54.76%

Average Trading Volume: 917,950

Technical Sentiment Signal: Sell

Current Market Cap: HK$2.21B

Learn more about 1061 stock on TipRanks’ Stock Analysis page.